Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
African Forests Have Become a Source of Carbon Emissions - 2Tesla Germany Registrations Quadruple to 9,252 Vehicles in Best March Ever
- 3'War is not over': Detailed diagrams of prisons found in cells of Oct. 7 terrorists
- 4FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- 5IDF destroys Hamas shaft in northern Gaza with loaded 'ready to fire' rocket aimed at Sderot
- Saturn's moon Titan may not have a buried ocean as long suspected, new study suggests
- What's your biological age? Experts explain the benefits and risks of at-home tests
- New COVID-19 variant 'Cicada' is spreading. What to know about BA.3.2.
- The 15 Most Powerful Forerunners in Business
- They died 'doing what they loved': The stories of workers in their 80s who died on the job
- Kennedy approves adding two rare disorders to newborn screenings
- UK, Canada, Germany, others condemn Israel's West Bank settlement plan
- Creative Do-It-Yourself Ventures for Each Expertise Level
- Yasser Abu Shabab's killing raises questions about Israel's militia strategy in Gaza
